Abstract:
The invention relates to a method for decarboxylating C-C cross-linking by reacting carboxylic salts with carbon electrophiles in the presence of transition metal compounds as catalysts. The method represents a decarboxylating cross-coupling of carboxylic acid salts with carbon electrophiles, wherein the catalyst contains two transition metals and/or transition metal compounds, from which one is present, preferably, in the oxidation step, which are different from each other by one unit, and catalyses a radical decarboxylation which is absorbed during the second oxidation steps, which are different from each other by two units and catalyses the two electron processes of a cross-linking reaction.
Abstract:
A method of producing hydrofluorocarbons and methods of producing other commercially attractive compounds formed as by-products of hydrofluorocarbon production by using aldehydes as a principal reactant.
Abstract:
Disclosed herein are polymers made by free radically polymerizing the novel compound vinyl(perfluorocyclopropane), and optionally other monomers to form copolymers. The repeat unit formed by vinyl(perfluorocyclopropane) contains an olefinic bond, making it particularly useful as a grafting and/or crosslinking site.
Abstract:
The present invention relates to therapeutically active heterocyclic compounds of formula (I), wherein n is 0, 1 or 2; and X is -O-, -S, -N(R )- or -CH2-; and R is H, NH2, NHR or OH; and R and R independently are H, COOH; COOR , CONH2, CONHR , CON(R )2, CONHSO2R or tetrazole; and R is H, OH, NH2, NHR ; CF3, C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, C3-6-cycloalkyl, phenyl or C1-4-alkoxy; and R is H, C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, phenyl or C3-6-cycloalkyl; and ring A can be partly or completely saturated or aromatic, or a salt thereof with a pharmaceutically acceptable acid or base, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system related to the metabotropic glutamate receptor system.